business

Dr. Reddy’s inks pact to market Takeda’s novel gastrointestinal drug Vonoprazan in India

On Jul 19, 2024 By The Hindu Bureau

Drugmaker Dr. Reddy’s Laboratories has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to commercialise Vonoprazan tablets in India.

A novel, orally active potassium competitive acid blocker (PCAB) Vonoprazan is used to treat reflux esophagitis and other acid peptic disorders, Dr. Reddy’s said in a release on Thursday. It will market Vonoprazan tablets, in 10mg and 20mg strengths, under its own trademark Vono.

“Leveraging our expertise in this [gastrointestinal segment] therapy area, pleased to make the first-in-class drug Vonoprazan [Vono] available to patients in India. The non-exclusive patent licensing agreement with Takeda is part of our continuous efforts to make innovative medicines available to patients in India through strategic collaborations,” said M.V. Ramana, CEO – Branded Markets (India & Emerging Markets) of Dr. Reddy’s.

Disclaimer: The copyright of this article belongs to the original author. Reposting this article is solely for the purpose of information dissemination and does not constitute any investment advice. If there is any infringement, please contact us immediately. We will make corrections or deletions as necessary. Thank you.